**
In a groundbreaking initiative, the United States military is set to investigate the use of MDMA-assisted therapy for active-duty service members suffering from post-traumatic stress disorder (PTSD). Funded by the Department of Defense (DoD), this pioneering research aims to provide vital support to soldiers grappling with the psychological scars of combat, potentially reshaping treatment protocols within the armed forces.
Groundbreaking Research into Psychedelic Therapy
The upcoming studies, involving 186 service personnel diagnosed with PTSD, are slated to commence next year. This innovative approach represents a significant shift in how the military addresses mental health challenges. Sean O’Keefe, the deputy under secretary of war for personnel and readiness, is closely monitoring the research, which includes training therapists from both the DoD and Veterans Affairs (VA) to administer psychedelic-assisted therapy.
Rick Doblin, the founder of the Multidisciplinary Association for Psychedelic Studies (MAPS), expressed optimism about the potential of MDMA therapy to assist soldiers in processing trauma. “Helping people process trauma, whoever they are, is probably better than not,” he stated. He emphasised the ethical imperative of aiding those who sacrifice for their country, underscoring the nobility of their service.
Legislative Support and Initiatives
This initiative gained momentum when former President Joe Biden included provisions for psychedelic research in the National Defence Authorization Act signed in December 2023. The bill, backed by Republican Congressman Morgan Luttrell, highlights the urgent need for comprehensive mental health support for military personnel. Luttrell, a veteran Navy SEAL who has experienced psychedelic therapy himself, remarked, “Our men and women in uniform deserve every tool available to heal and stay in the fight. This is just the beginning.”
The urgency surrounding this research was further amplified during a recent executive order signed by Donald Trump, aimed at expediting psychedelic research and expanding access to veterans. Trump lamented the tragic statistics surrounding veteran suicides, stating that “we’ve lost over 21 times more veteran lives to suicide than on the battlefield” since the events of 9/11.
Historical Context and Concerns
Historically, the military has employed various methods to treat PTSD, including barbiturates during World War II. However, these approaches have been largely ineffective in providing lasting relief. The advent of MDMA and other psychedelics, which show promise in addressing mental health issues, raises ethical questions about their application in enhancing combat readiness.
Ethnobotanist Dennis McKenna cautioned against using psychedelic therapy solely as a means to restore soldiers for combat, describing it as “completely cynical and cruel.” He warned that sending individuals back into combat after treatment could lead to further trauma. Doblin echoed this sentiment, noting that soldiers who return to high-stress environments may be more susceptible to relapsing into PTSD.
Global Perspectives and Future Implications
In Ukraine, MAPS has already trained 55 therapists to facilitate MDMA therapy sessions for soldiers, reflecting a growing recognition of the need to address untreated PTSD within military ranks. Although MDMA-assisted therapy is not yet legal in Ukraine, many troops have benefitted from legal ketamine therapy aimed at alleviating PTSD symptoms.
The two upcoming MDMA studies in the US will be the first of their kind to systematically investigate the effects of psychedelics on soldiers. With funding of $4.9 million each for the Walter Reed National Military Medical Center and Emory University, these studies could pave the way for standardised psychedelic therapy within military settings.
Experts like psychologist Rachel Yehuda highlight the transformative potential of such therapy, noting that it could lead soldiers to re-evaluate their military service. However, she also cautioned that the treatment context differs significantly between ongoing trauma and its aftermath.
Why it Matters
The exploration of MDMA-assisted therapy for active-duty soldiers marks a significant shift in military mental health treatment. As the armed forces confront the psychological toll of warfare, integrating innovative therapies could revolutionise support systems for service members, potentially reducing the alarming rates of PTSD and suicide within the ranks. This initiative not only reflects a growing acceptance of alternative therapies but also raises important ethical discussions about the responsibilities of those who serve in combat. The outcomes of this research could have profound implications for the future of military healthcare and the wellbeing of veterans.
